PL374525A1 - Nukleozydy, wytwarzanie nukleozydów i zastosowanie jako inhibitorów polimeraz wirusowych RNA - Google Patents

Nukleozydy, wytwarzanie nukleozydów i zastosowanie jako inhibitorów polimeraz wirusowych RNA

Info

Publication number
PL374525A1
PL374525A1 PL02374525A PL37452502A PL374525A1 PL 374525 A1 PL374525 A1 PL 374525A1 PL 02374525 A PL02374525 A PL 02374525A PL 37452502 A PL37452502 A PL 37452502A PL 374525 A1 PL374525 A1 PL 374525A1
Authority
PL
Poland
Prior art keywords
alkyl
inhibitors
rna viral
viral polymerases
aryl
Prior art date
Application number
PL02374525A
Other languages
English (en)
Inventor
Yarlagadda S. Babu
Pooran Chand
Yahya El-Kattan
Minwan Wu
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Publication of PL374525A1 publication Critical patent/PL374525A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL02374525A 2001-11-14 2002-11-14 Nukleozydy, wytwarzanie nukleozydów i zastosowanie jako inhibitorów polimeraz wirusowych RNA PL374525A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33132201P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
PL374525A1 true PL374525A1 (pl) 2005-10-31

Family

ID=29250434

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02374525A PL374525A1 (pl) 2001-11-14 2002-11-14 Nukleozydy, wytwarzanie nukleozydów i zastosowanie jako inhibitorów polimeraz wirusowych RNA

Country Status (12)

Country Link
US (2) US20050033051A1 (pl)
EP (1) EP1450809A4 (pl)
JP (1) JP2005519983A (pl)
KR (1) KR20040054775A (pl)
AU (1) AU2002365935A1 (pl)
CA (1) CA2466301A1 (pl)
EA (1) EA200400690A1 (pl)
HU (1) HUP0501070A2 (pl)
IL (1) IL161901A0 (pl)
MX (1) MXPA04004621A (pl)
PL (1) PL374525A1 (pl)
WO (1) WO2003087298A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20050033051A1 (en) * 2001-11-14 2005-02-10 Babu Yarlagadda S Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
EP1656387A2 (en) 2003-07-30 2006-05-17 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
KR20150103335A (ko) * 2003-08-28 2015-09-09 수퍼랩 파 이스트 리미티드 변경된 공간 구조를 갖는 인터페론의 용도
UY28758A1 (es) 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
US20080124302A1 (en) * 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
KR101675462B1 (ko) * 2011-11-22 2016-11-14 한국생명공학연구원 염기, 뉴클레오사이드 또는 뉴클레오타이드를 유효성분으로 포함하는 항바이러스용 약학적 조성물
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
AU2017231824B2 (en) * 2016-03-09 2021-07-01 Alios Biopharma, Inc. Acyclic antivirals
CN108948084B (zh) * 2017-05-19 2020-10-20 浙江司太立制药股份有限公司 替诺福韦双-l-氨基酸酯及其制备方法
CA3164122A1 (en) * 2019-12-11 2021-06-17 Immunolux International Corp. Vaccinia viral polymerase-mediated viral replication
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
AU613592B2 (en) * 1986-11-18 1991-08-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosophonomethoxy-alkyene purine and pyrimide derivatives
US5284837A (en) * 1988-05-06 1994-02-08 Medivir Ab Derivatives of purine, process for their preparation and a pharmaceutical preparation
US5189039A (en) * 1989-11-29 1993-02-23 Biocryst, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo[3,2d]pyrimidine and pharmaceutical uses and compositions containing the same
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
WO1995007919A1 (en) * 1993-09-17 1995-03-23 Gilead Sciences, Inc. Method for dosing therapeutic compounds
CA2224710A1 (en) * 1995-06-15 1997-01-03 Naoko Inoue Phosphonate nucleotide derivatives
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
CN1291994C (zh) * 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
US20040023928A1 (en) * 2001-10-31 2004-02-05 Colacino Joseph Matthew Phosphonate nucleotide and thiadiazole compounds for the treatment of smallpox
US20050033051A1 (en) * 2001-11-14 2005-02-10 Babu Yarlagadda S Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
US20050080053A1 (en) * 2003-08-29 2005-04-14 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases

Also Published As

Publication number Publication date
EA200400690A1 (ru) 2005-06-30
IL161901A0 (en) 2005-11-20
EP1450809A2 (en) 2004-09-01
MXPA04004621A (es) 2004-09-10
EP1450809A4 (en) 2006-07-19
US20040014722A1 (en) 2004-01-22
JP2005519983A (ja) 2005-07-07
KR20040054775A (ko) 2004-06-25
CA2466301A1 (en) 2003-10-23
HUP0501070A2 (en) 2006-04-28
US20050033051A1 (en) 2005-02-10
AU2002365935A1 (en) 2003-10-27
WO2003087298A3 (en) 2003-12-24
WO2003087298A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
TNSN06065A1 (en) Interfering rna duplex having blunt-ends and 3' - modifications
TW200519088A (en) Aryl or heteroaryl amide compounds
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
GR3034398T3 (en) 2-[1',2',4'-triazol-3'-yloxymethylene]-anilides and their use as pest-control agents
TW200604558A (en) (Meth)acrylamide monomers containing hydroxy and silicone functionalities
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
RU2009139920A (ru) Изоксазолиновые соединения и их применение в борьбе с вредителями
WO2008078678A1 (ja) オキシムエステル化合物及び該化合物を含有する光重合開始剤
IL143157A0 (en) Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural bactericides
EA200300559A1 (ru) Производные цианопирролидина
UA98326C2 (ru) Способ получения амидного соединения, промежуточные соединения, амидное соединение, его применение, пестицидная композиция и способ борьбы с вредными членистоногими
EA201200031A1 (ru) Инсектицидные соединения
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
DE60137540D1 (de) Methoden zur behandlung von angstzuständen
SG170049A1 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
BR8503835A (pt) Processo de preparacao de composto e composicoes destinadas a luta contra insetos,acarideos e nematodeos
DK1282596T3 (da) Fremstilling af iminodieddikesyreforbindelser ud fra monoethanolaminsubstrater
MXPA02012405A (es) Inhibidores de integrasa del virus de inmunodeficiencia humana.
PL357341A1 (pl) Kompozycje herbicydów i środków zabezpieczających
TW200510305A (en) Process for the preparation of CPLA2 inhibitors
EP2266971A3 (en) Hiv protease inhibiting compounds
GB0807305D0 (en) Compounds for use in therapy
MXPA04000657A (es) Proceso para obtener amidas n-monosustituidas.
TWI265161B (en) Oxime compounds, their use, and intermediates for their production